© UKHD
Dr. Med.

Matthias Dewenter

Projects:

Institute of Experimental Cardiology
Medical Faculty Heidelberg, Heidelberg University
Germany
Eppelheimer Str. 8
69115 Heidelberg

Research Interests

Selected Coordinating Functions and Awards

Since 2023
Founder, Revier Therapeutics
Since 2019
Head of Preclinical in vivo model core, Institute of Experimental Cardiology, Heidelberg University, Germany
2019-2022
Physician scientist program of the Medical Faculty Heidelberg
2018
German Society of Cardiology (DKG) Forschungsstipendium
2018
Dissertation Award, Medical Faculty Göttingen (Verein der Freunde und Förderer der Medizinischen Fakultät Göttingen)
2013
Doctoral scholarship in the CRC 1002 (‘Modulatory Units in Heart Failure’)
2019-2022
Project leader and Co-PI DZHK Translational Research Project “Hit-to-lead development of CaMKII-HDAC4 inhibitory compounds to treat heart failure”

CRC1550 Related Publications

2022

Deep phenotyping of two preclinical mouse models and a cohort of RBM20 mutation carriers reveals no sex-dependent disease severity in RBM20 cardiomyopathy

Lennermann DC, Pepin ME, Grosch M, Konrad L, Kemmling E, Hartmann J, Nolte JL, Clauder-Munster S, Kayvanpour E, Sedaghat-Hamedani F, Haas J, Meder B, van den Boogaard M, Amin AS, Dewenter M, Kruger M, Steinmetz LM, Backs J & van den Hoogenhof MMG

Am J Physiol Heart Circ Physiol. 323:H1296-H310, 2022.